Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Eur J Med Chem ; 254: 115386, 2023 Jun 05.
Artigo em Inglês | MEDLINE | ID: mdl-37094450

RESUMO

The modulatory interactions between neurotensin (NT) and the dopaminergic neurotransmitter system in the brain suggest that NT may be associated with the progression of Parkinson's disease (PD). NT exerts its neurophysiological effects by interactions with the human NT receptors type 1 (hNTS1) and 2 (hNTS2). Therefore, both receptor subtypes are promising targets for the development of novel NT-based analogs for the treatment of PD. In this study, we used a virtually guided molecular modeling approach to predict the activity of NT(8-13) analogs by investigating the docking models of ligands designed for binding to the human NTS1 and NTS2 receptors. The importance of the residues at positions 8 and/or 9 for hNTS1 and hNTS2 receptor binding affinity was experimentally confirmed by radioligand binding assays. Further in vitro ADME profiling and in vivo studies revealed that, compared to the parent peptide NT(8-13), compound 10 exhibited improved stability and BBB permeability combined with a significant enhancement of the motor function and memory in a mouse model of PD. The herein reported NTS1/NTS2 dual-specific NT(8-13) analogs represent an attractive tool for the development of therapeutic strategies against PD and potentially other CNS disorders.


Assuntos
Neurotensina , Doença de Parkinson , Animais , Humanos , Camundongos , Dopamina , Ligantes , Neurotensina/farmacologia , Neurotensina/metabolismo , Doença de Parkinson/tratamento farmacológico , Ligação Proteica , Receptores de Neurotensina/metabolismo
2.
Z Naturforsch C J Biosci ; 64(3-4): 179-85, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19526709

RESUMO

The series of complexes: cis-[Pd(PMSA)2X2], cis-[Pt(PMSA)2X2], trans-[Pt(PMSA)2I2] and [Pt(PMSA)4]Cl2 (PMSA = N-3-pyridinylmethanesulfonamide; X = Cl, Br, I), previously synthesized and characterized by us, as well as the free ligand PMSA, were tested for their cytotoxic activity without electroporation -- against murine leukemia F4N and human SKW-3 and MDA-MB-231 tumour cell lines -- and with electroporation -- against the latter two cell lines. The majority of the complexes exhibited cytotoxic effects (IC50 < 100 micromol/l) under the conditions of electroporation. Both cis- and trans-[Pt(PMSA)2I2] had pronounced cytotoxic effects (29-61 micromol/l against MDA-MB-231 cells).


Assuntos
Antineoplásicos/toxicidade , Paládio/toxicidade , Compostos de Platina/toxicidade , Sulfonamidas/toxicidade , Animais , Ciclo Celular/efeitos dos fármacos , Linhagem Celular Tumoral/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Eletroporação/métodos , Humanos , Leucemia Eritroblástica Aguda , Leucemia de Células T , Camundongos , Modelos Moleculares , Pirrolidinas/toxicidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA